Atrial fibrillation: will new drugs and patient choice improve anticoagulation outcomes?
The growing epidemic of atrial fibrillation presents major challenges to the healthcare community, both clinical and financial.
Fuller
R
R
Dudley
N J
NJ
D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications*; D001384:Azetidines / Q000627:therapeutic use; D001596:Benzylamines; D006801:Humans; D010358:Patient Participation; D018570:Risk Assessment / Q000379:methods; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D013917:Thrombin / Q000037:antagonists & inhibitors; D016896:Treatment Outcome
D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; C426686:ximelagatran; D013917:Thrombin